Vernalis Restructures, Gives Up U.S. Frova Rights To Increase Cash Reserves
This article was originally published in The Pink Sheet Daily
Executive Summary
UK company's decision to lay off almost half its workforce, divest Parkinson's therapy Apokyn and shut down U.S. operations stems from "not approvable" letter for Frova last fall for menstrual migraine.
You may also be interested in...
Oncology Target Option Deal With GSK Helps Vernalis Hit Comeback Trail
UK biotech gets $6 million upfront, half of which is structured as an equity investment by GSK.
Oncology Target Option Deal With GSK Helps Vernalis Hit Comeback Trail
UK biotech gets $6 million upfront, half of which is structured as an equity investment by GSK.
UK Biotech Proximagen Raises Record $80 Million ‘Asset Acquisition’ Fund
In one of the U.K.’s largest fundraisings, Proximagen avoids paying a discount to its share price. Proceeds will buy CNS pipeline assets.